News & Events

Extranet


FP7
HIVINNOV (Grant n°305137) is a collaborative research project supported by the European Union


Dual inhibition of HIV-1 replication by integrase-LEDGF allosteric inhibitors is predominant at the post-integration stage.

 

 

Biodim's research team has published a new article in Retrovirology (PMID : 42461564)

 

"Dual inhibition of HIV-1 replication by integrase-LEDGF allosteric inhibitors is predominant at the post-integration stage."

 

http://www.retrovirology.com/content/10/1/144

 

The full text is freely available.

 

 

 

 

 

Curing hiv/aids gets tougher: study shows far more ‘hidden’ and potentially active virus than once thought

 

 

Johns Hopkins Medicine - 25 October 2013

 

In a cover-story report on the research to be published in the journal Cell online Oct. 24, Johns Hopkins infectious disease experts say the amount of potentially active, dormant forms of HIV hiding in infected immune T cells may actually be 60-fold greater than previously thought.

 

Read More (on Hopkins Medicine website)

 

 

 

AIDS vaccine candidate appears to completely clear virus from the body in SIV cases

September 20th 2013

 

Dr Louis Picker and his team (Oregon Health & Science University) have published in Nature last week  a study on a SIV vaccine that appear to cure the

monkeys injected with SIV protein-expressing rhesus cytomegalovirus (RhCMV/SIV).

 

Read More (Nature)

(Medical News Today) 

 

 

FDA Approves ViiV HIV Integrase Inhibitor Dolutegravir

August 12th 2013

 

The U.S. Food and Drug Administration (FDA) today (August 12, 2013) approved the second HIV integrase inhibitor, dolutegravir, which will be marketed under the brand name Tivicay by ViiV Healthcare. Phase 3 studies showed that dolutegravir works as well as raltegravir (Isentress) or Atripla and is generally safe and well-tolerated.

 

Read more...

 

A therapeutic denditric cell vaccine for HIV-1 infection controls virus replication temporarily

 

January 2nd 2013

 

Investigators from the AIDS and Infectious Diseases team of the Hospital Clínic/IDIBAPS at University of Barcelona, led by Dr. Josep Maria Gatell (HIVinnov partner N° 6), report today in Science Translational Medicine the safety, tolerability, immunogenicity and virologic response results obtained with a new therapeutic vaccine candidate.

 

Read more ...

 

gatell garcia gallart

 

Kick Off meeting

November 7-8th 2012

 

The HIVinnov consortium held its Kick-Off meeting On November 7-8th 2012 in Biodim's R&D facility (Romainville, France).

 

HIVinnov Kick Off Meeting-small-landscape

 

Dolutegravir works as well as raltegravir for first-time HIV treatment

January 13th 2013

 

The next-generation HIV integrase inhibitor dolutegravir worked as well as raltegravir (Isentress), an approved drug in this class, for treatment-naive people in the Phase 3 SPRING-2 trial, according to a report published in the January 8, 2013, advance edition of The Lancet.

Source : The Lancet, hiv&hepatitis,


Read More ...

 

 620px-Dolutegravir.svg

 

Patient satisfaction leads to better HIV care

February 4th 2013

 

In a study of patients at two HIV clinics in the Houston area, researchers at Baylor College of Medicine and the Michael E. DeBakey Veterans Affairs Medical Center found that those who were satisfied with the care they received had higher adherence to care and higher retention rates. The full report appears today in PLOS ONE.

 

Source : Baylor College of Medicine based on original article on PLOS ONE

 

Read More ...